Representatives Paul Tonko, D-New York, and Rob Gibbs, R-Ohio, have introduced H.R. 4629, the Star Ratings for Biosimilars Act, in the House. The bipartisan bill would require HHS to evaluate Medicare Advantage (MA) plans based on whether biosimilars are available to enrollees.
Representatives Paul Tonko, D-New York, and Rob Gibbs, R-Ohio, have introduced H.R. 4629, the Star Ratings for Biosimilars Act, in the House. The bipartisan bill would require HHS to evaluate Medicare Advantage (MA) plans based on whether biosimilars are available to enrollees.
Under the proposed legislation, which would amend title 18 of the Social Security Act, starting in 2021, HHS would add a new set of measures to the current 5-star rating system based on biosimilar access in Part B and, for MA plans that offer prescription drug coverage, in Part D.
The measures include assessing the following: whether a biosimilar is on the formulary in lieu of or in addition to the reference, tier placement or cost-sharing for biosimilars relative to the reference, whether and how utilization management is applied, and the percentage of enrollees prescribed biosimilars rather than references.
The bill has now been referred to the Committee on Energy and Commerce and the Committee on Ways and Means.
According to a statement by Tonko, “certain profitable dynamics in America’s health care system are blocking access to these cost saving alternatives, meaning our patients and their families are forced to pay a higher price for substantially similar medical care. My bill will highlight the existing barriers in current health plans, provide for meaningful transparency where plans fall short, and allow for reform to unlock the billions in savings for America’s patients and taxpayers."
Trade group the Biosimilars Forum praised the provisions, saying in a statement on the bill that “CMS must take this opportunity to save seniors and taxpayers money. Congressmen Tonko and Gibbs understand the importance of identifying inefficiencies in health plans that are blocking patient access and use of lower-cost biosimilars to treat some of life’s most complex illnesses. Through this measurement, it will allow for reforms that will encourage health plans to drive significant savings in health care.”
In the Senate, parallel provisions have been put forth under S.2543, or the Prescription Drug Pricing Reduction Act of 2019, sponsored by Senator Chuck Grassley, R-Iowa. The Senate bill was introduced in the Senate in September, and which has been placed on the Senate legislative calendar under general orders.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
FTC Releases Second Report on PBMs Meddling in Generic Drug Markets
January 19th 2025The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the Federal Trade Commission (FTC)’s second interim report on PBM practices.
Improving Biosimilar Access Through Global Regulatory Convergence
January 15th 2025Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access, reducing costs, and enhancing patient outcomes by streamlining approval processes, fostering international collaboration, and addressing regulatory disparities.